Compare Rivian Automotive, Inc. (RIVN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Rivian Automotive, Inc. trades at $14.2 (market cap $20.75B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.1× Rivian Automotive, Inc.'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rivian Automotive, Inc. for 61 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RIVN | VRTX | |
|---|---|---|
Market Cap | $20.75B | $127.55B |
Volume | 26,144,654 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $557.96 |
52-Week Low | $12.50 | $407.37 |
Typical Hold Time | 61 Days | 120 Days |
Enterprise Value | $20.79B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $14.34, down 1.17% amid bearish technical signals despite strong Q3 2026 delivery growth of 46% to 19,248 vehicles. The company maintains negative profitability with a -54.95% net income margin but shows improving cash flow trends with operating losses narrowing from -$5.1B in 2022 to -$779M in 2025. Recent news highlights R2 SUV production ramp and autonomy technology development, though the stock faces pressure from unchanged 2026 guidance and a recent R2 battery pack recall.
Rivian presents a high-risk growth opportunity with significant cash burn but improving operational efficiency. The path to profitability depends on successful R2 scaling and future autonomy revenue, while near-term risks include execution challenges and competitive EV market pressures. Analyst consensus remains cautiously optimistic with a $16.89 price target representing 18% upside potential.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
